DNAtrix is developing modified viruses for the treatment of the most aggressive forms of cancer. Since viruses are already efficient at killing cells, scientists have harnessed this ability by modifying a common cold virus so that it targets and selectively kills cancer cells.
Missing: DNAtriX's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: DNAtriX's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing DNAtriX
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
DNAtriX is included in 3 Expert Collections, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.
DNAtriX has filed 15 patents.
Monoclonal antibodies, Experimental cancer drugs, Monoclonal antibodies for tumors, Cancer treatments, Oncology
Monoclonal antibodies, Experimental cancer drugs, Monoclonal antibodies for tumors, Cancer treatments, Oncology
Latest DNAtriX News
Nov 28, 2022
| DelveInsight News provided by Share this article Share this article The glioblastoma multiforme market is expected to witness a significant positive shift owing to the positive outcomes of the several products during the developmental stage by key players such as Bayer, VBL Therapeutics, AstraZeneca, DNAtrix, Kintara Pharmaceuticals, Chimerix, Karyopharm, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Immunomic Therapeutics, Istari Oncology, Inovio Pharmaceuticals, Northwest Biotherapeutics, and others. LAS VEGAS, Nov. 28, 2022 /PRNewswire/ -- DelveInsight's Glioblastoma Multiforme Market Insights report includes a comprehensive understanding of current treatment practices, glioblastoma multiforme emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Key Takeaways from the Glioblastoma Multiforme Market Report As per DelveInsight analysis, the glioblastoma multiforme market size in the 7MM was approximately USD 799 million in 2021. According to the assessment done by DelveInsight, the estimated total glioblastoma multiforme incident cases in the 7MM were approximately 32.5K in 2021. Leading glioblastoma multiforme companies such as Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Biotherapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, TME Pharma, Novocure, Genentech, Daiichi Sankyo, Novartis, and others are developing novel glioblastoma drugs that can be available in the glioblastoma multiforme market in the coming years. The promising glioblastoma multiforme therapies in the pipeline include Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, LAM561 (2-OHOA), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, VAL-083 (dianhydrogalactitol), MDNA55, Paxalisib (GDC-0084), Temferon, EO2401, INO-5401 + INO-9012 + LIBTAYO (cemiplimab), Delytact (Teserpaturev/DS-1647), TAFINLAR + MEKINIST, VBI-1901, and others. The current therapeutic landscape of GBM in the United States is driven by the current treatment paradigm, which includes therapies such as radiation, bevacizumab, temozolomide, and OPTUNE, as mono or combination therapies, as well as several other systemic therapies. In October 2022, NovAccess Global's TLR-AD1 Orphan Drug Application was approved by the FDA. The FDA broadens the scope of the company's submission, accelerating the path to immunotherapy for glioblastoma. In October 2022, Black Diamond Therapeutics announced the presentation of three posters reporting new preclinical data on BDTX-1535 and BDTX-4933 at the 34th European Organization for Research and Treatment of Cancer—National Cancer Institute—American Association for Cancer Research (EORTC-NCI-AACR) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. In October 2022, Oblato, a Korean subsidiary of HLB Therapeutics, announced that it has completed enrollment of recurrent GBM patients in Phase II clinical trial with its proprietary compound OKN-007 in the United States. In August 2022, Northwest Biotherapeutics announced that the Pediatric Investigation Plan (PIP) had been approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA). The company's approved PIP includes two clinical trials: one for newly diagnosed pediatric HGG, and one for recurrent pediatric HGG. In each of the two pediatric trials, 24 patients will be treated with DCVax-L on the same treatment schedule as in the company's Phase III trial in adult glioblastoma patients. In June 2022, Novartis announced that the US FDA had granted TAFINLAR (dabrafenib) + MEKINIST (trametinib) accelerated approval for the treatment of advanced tumors with the "BRAF V600E" mutation. The approval includes use in both adult and pediatric (over the age of six) high- and low-grade glioma patients with this mutation whose tumors progressed after prior treatment. In May 2022, Kintara Therapeutics announced that the VAL-083 treatment arm in the GBM adaptive global innovative learning environment (GBM AGILE) registrational Phase II/III clinical trial for GBM had activated its first European site. In November 2021, Chimerix announced positive data in recurrent H3 K27M-mutant Diffuse Midline Glioma to be presented at the Society for Neuro-Oncology Annual Meeting. Discover which therapies are expected to grab the major glioblastoma multiforme market share @ Glioblastoma Multiforme Market Report Glioblastoma Multiforme Overview Glioblastoma, also known as glioblastoma multiforme is a cancer that can develop in the brain or spinal cord. Glioblastoma develops from astrocytes, which are nerve cell-feeding cells. It can occur at any age, but it is more common in the elderly. It can make headaches, nausea, vomiting, and seizures worse. The causes of glioblastoma are unknown. Glioblastoma symptoms vary depending on tumor type, size, location, and growth rate. Headache, nausea or vomiting, confusion or deterioration in brain function, memory loss, personality changes or irritability, and difficulty balancing are all common glioblastoma symptoms. Computed tomography (CT or CAT scan) and magnetic resonance imaging (MRI) are two diagnostic tools used for glioblastoma diagnosis. Glioblastoma treatments may slow cancer progression and alleviate symptoms. Glioblastoma Multiforme Epidemiology Segmentation DelveInsight estimates that there were approximately 32.5K incident cases of glioblastoma multiforme in the 7MM in 2021. Among the EU-4 countries, the incident population of GBM was found to be the maximum in Germany in 2021. The glioblastoma multiforme market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Incident Cases Incident Cases based on Histologic Classification of GBM Download the report to understand which factors are driving glioblastoma multiforme epidemiology trends @ Glioblastoma Multiforme Epidemiological Insights Glioblastoma Multiforme Treatment Market Glioblastoma multiforme is typically treated with a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Although rarely used alone, surgery is usually one of the most important aspects of glioblastoma treatment. Because glioblastomas grow so quickly, they are frequently difficult to remove completely. As a result, surgery is performed to achieve the best possible safe resection - removing as much of the tumor as possible while preserving brain function and sparing healthy tissues. Following surgery, residual cancer cells can be targeted with additional treatments such as chemotherapy or radiation therapy. Once the tumor's diagnosis or name is determined, radiation therapy and chemotherapy are usually administered. These are known as adjuvant glioblastoma treatments. Because this multispecialty approach can have several side effects, steroids are frequently used as an additional component of glioblastoma treatment to help alleviate the side effects of other therapies. Chemotherapy is a common type of glioblastoma treatment. Patients typically begin chemotherapy 2-4 weeks after surgery, at the same time as or shortly after radiation therapy. When a tumor cannot be surgically removed, chemotherapy is sometimes used as the primary glioblastoma treatment. Cytotoxic drugs include Carmustine (BCNU), Lomustine (CCNU), or Gleostine (Generic), Gliadel wafer (biodegradable discs infused with BCNU), Temozolomide (Temodar), Cisplatin, Carboplatin, Etoposide, and Irinotecan. To know more about glioblastoma treatment options, visit @ Glioblastoma Treatment Drugs Glioblastoma Multiforme Pipeline Therapies and Key Companies Regorafenib: Bayer The dynamics of glioblastoma multiforme market is predicted to change in the coming years owing to the improvement in the research and development activities so that glioblastoma multiforme market will comprise of efficient glioblastoma treatment options. Moreover, the anticipated launch of emerging therapies during the forecast period is further expected to fuel the glioblastoma multiforme market growth. Furthermore, vaccine approaches are appealing as adjuvant therapy for solid tumors because they can generate long-term immune surveillance against cancer cells. MimiVax (SurVaxM), Immunomic Therapeutics (ITI-1000), and IMVAX (IGV-001) are among the companies developing therapeutic vaccines for glioblastoma multiforme. Forbye, the introduction of bevacizumab biosimilars has resulted in a decrease in the cost burden. Numerous failed clinical trials indicate that combination therapies are likely to be the most promising method of glioblastoma treatment, with an emphasis on drug design and pharmacokinetic properties. Furthermore, better prognostic markers would allow physicians to diagnose and treat GBM earlier, potentially preventing disease progression and thereby boosting the glioblastoma multiforme market growth. However, several factors are impeding the growth of the glioblastoma multiforme market. There is a lack of a reliable biomarker that can aid in the diagnosis, patient stratification, recurrence detection, and therapy response. As a result, biomarkers are required to overcome the disease's complexity and allow for minimally invasive detection and analysis. As the glioblastoma multiforme market lacks an effective strategy for curing GBM, the survival rate of patients diagnosed with GBM remains low. Even after using approved therapies, GBM patients have a low survival rate. Furthermore, gliomas' molecular and cellular complexity severely limits diagnosis and treatment. This is exacerbated by significant intertumoral and intratumoral heterogeneity, which has a negative impact on the ability to develop effective and reliable disease biomarkers. Hence these factors mentioned above may hinder the growth of the glioblastoma multiforme market. Report Metrics USD 799 million Key Glioblastoma Multiforme Companies Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Biotherapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, TME Pharma, Novocure Limited, Genentech, Daiichi Sankyo, Novartis, and others Key Pipeline Glioblastoma Multiforme Therapies Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, Ofranergene Obadenovec (VB-111), LAM561 (2-OHOA), MEDI4736 (durvalumab), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), IGV-001, SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, SONALA-001 + Exablate 2.0 Device, VAL-083 (dianhydrogalactitol), Pomalidomide, MDNA55, BMX-001, Lenvatinib ± Pembrolizumab, Paxalisib (GDC-0084), OKN-007, Temferon, EO2401, INO-5401+ INO-9012+ LIBTAYO (cemiplimab), Selinexor (KPT-330), Olutasidenib (FT-2102), VBI-1901, NOX-A12/olaptesed pegol, and others Scope of the Glioblastoma Multiforme Market Report Therapeutic Assessment: Glioblastoma Multiforme current marketed and emerging therapies Glioblastoma Multiforme Market Dynamics: Glioblastoma Multiforme market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Glioblastoma Multiforme Market Access and Reimbursement Discover more about glioblastoma drugs in development @ Glioblastoma Clinical Trials Table of Contents
DNAtriX Frequently Asked Questions (FAQ)
When was DNAtriX founded?
DNAtriX was founded in 2005.
Where is DNAtriX's headquarters?
DNAtriX's headquarters is located at 2450 Holcombe Blvd., Houston.
What is DNAtriX's latest funding round?
DNAtriX's latest funding round is Loan.
How much did DNAtriX raise?
DNAtriX raised a total of $38.88M.
Who are the investors of DNAtriX?
Investors of DNAtriX include Paycheck Protection Program, Mercury Fund, Morningside Ventures, Targeted Technology, JLabs and 4 more.
Who are DNAtriX's competitors?
Competitors of DNAtriX include Catalyst Biosciences, NGM Biopharmaceuticals, Jennerex Biotherapeutics, ACT Biotech, Telormedix and 11 more.
Compare DNAtriX to Competitors
Qyntessa Biologics aims to provide clinical manufacturing, (cGMP biologics manufacturing), process development, cell banking, cell line development, testing and fill/finish for researchers and biopharmaceutical companies who do not have the facilities and competencies for clinical manufacturing.
LungLife AI is focused on the development of the LiquidBiopsy platform, a high-performance rare cell isolation technology for biomedical research and cancer diagnostics. LiquidBiopsy is a key enabling technology to realize the promise of personalized medicine, including the early detection of disease, real-time monitoring of patients, and the selection of individual therapeutic solutions.
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.
CTI is committed to developing, acquiring, and commercializing innovative treatments for cancer. In the company's pursuit of making cancer more treatable, they are developing a diversified portfolio of oncology products focused on identifying and developing new, less toxic, and more effective ways to treat cancer.
Aliva Biopharmaceuticals is a company that received a SBIR Phase I grant for a project entitled: Humanized Mouse Ig system employing BAC. Their research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required. The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.